AtCor Medical - News 2008

AtCor Medical today announced that it has signed new agreements to supply SphygmoCor® systems and clinical trial support services to two leading international pharmaceutical companies. The minimum total value of the contracts is US $860,000 and US $650,000 respectively.

Please click here to view the ASX/media release

New Study Reveals Elevated Central Pulse Pressure in African-American Men

4 December 2008

AtCor Medical today responded to media reports on a study that compared vascular function in groups of healthy young African American and Caucasian men. The study found that while both groups of men had similar brachial cuff (measured at the arm) pulse pressures, the young African American men had higher central pulse pressures.

Please click here to view the ASX/media release

Change of Director's Interest Notice

3 December 2008

AtCor Medical today released a Change of Director's Interest Notice.

Please click here to view the ASX/media release

NIH Study Supports Central Blood Pressure as a Treatment Target

13 November 2008

AtCor Medical today announced that a new study funded by the National Institutes of Health (NIH), found that when patients’ central pulse pressures exceeded 50 mm of mercury, there was a significant increase in cardiovascular events.

Please click here to view the ASX/media release

Superior Predictor of Development of Atrial Fibrillation

12 November 2008

AtCor Medical today announced that a new study funded by the National Institutes of Health (NIH), has found that central pulse pressure is a stronger independent predictor of the first onset of atrial fibrillation than well-established clinical and echocardiographic risk factors.

Please click here to view the ASX/media release

Constitution Amendment

06 November 2008

AtCor Medical today amended its constitution as approved by shareholders at the Annual General Meeting held on 4 November 2008.

Please click here to view the ASX/media release

Directors' Interest Notices

06 November 2008

AtCor Medical today released a Final Director's Interest Notice and an Initial Director's Interest Notice.

Please click here to view the Final Director's Interest Notice

Please click here to view the Initial Director's Interest Notice

AtCor Medical Anticipates Continued Strong Growth in FY2009

5 November 2008

AtCor Medical yesterday announced that the company anticipated a 45 per cent increase in sales for FY2009 over FY2008.

Please click here to view the ASX/media release

US $0.5m New Pharmaceutical Trial Contract

3 November 2008

AtCor Medical today announced that it has signed a new agreement to supply SphygmoCor® systems and clinical trial support services to a leading international pharmaceutical company. The minimum total value of this contract is US $540,000, a large portion of which will be recognised in the current financial year. This new order brings the minimum total value of pharmaceutical trial contracts secured by AtCor in the past 150 days to over US $4.2 million.

Please click here to view the ASX/media release

AtCor to Target Specialists with Lightweight SphygmoCor

31 October 2008

AtCor Medical today announced that it will introduce portable SphygmoCor systems in early November. The new systems will be approximately one-quarter the size and weight of the company’s first-generation systems, and are designed to spearhead AtCor Medical’s push into the $US500 million global specialist clinical market.

Please click here to view the ASX/media release

New Study Supports Central Blood Pressure Measurement

29 October 2008

AtCor Medical today announced that a new study which examined the effects of drugs used to lower heart rate in hypertension further validates the importance of central blood pressure measurement.

Please click here to view the ASX/media release

AtCor Medical Announces First Quarter Report - Appendix 4C

20 October 2008

AtCor Medical today released its quarterly cash flow report for the period ending 30 September 2008.

Cash at quarter end was $3,326,000, up $10,000 from 30 June 2008.

Please click here to view the ASX/media release

US $0.9m New Pharmaceutical Trial Contract

08 October 2008

AtCor Medical today announced that it has signed a new agreement to supply SphygmoCor® systems and clinical trial support services to a leading international pharmaceutical company. The minimum total value of this contract is US$930,000, the majority of which will be recognised in the current financial year. This new order brings the minimum total value of pharmaceutical trial contracts secured by AtCor in the past 130 days to over US $3.7 million.

Please click here to view the ASX/media release

Annual Report 2008

03 October 2008

AtCor Medical today released its Annual Report for 2008. Highlights include:

Global sales increase to $6.5mill, or 47% in constant currency (cc).
North American sales increased 46% in the fiscal year and 138% in the 2nd half.
European sales grew 55% through expansion into Eastern Europe and greater productivity from current distributors.
Gross margin improved to 82.0% from 79.2% on a cc basis.
Operating expenses down 3% versus pcp, rising only 1% on a cc basis.
Cash usage reduced by $1 mill, due to improved customer receipts.
Important studies reported in support of clinical adoption.

Please click here to view the ASX/media release

Notice of Annual General Meeting / Proxy Form

03 October 2008

AtCor Medical today released its Annual General Meeting Notice and Proxy Form for 2008.

Please click here to view the ASX/media release

Change of Director's Interest Notice

01 October 2008

AtCor Medical today released a change of Director's Interest Notice.

Please click here to view the ASX/media release

Investor Presentation

29 September 2008

AtCor Medical today released their Investor Presentation for September 2008.

Please click here to view the ASX/media release

Change of Director's Interest Notice

16 September 2008

AtCor Medical today released a change of Director's Interest Notice.

Please click here to view the ASX/media release

ASX Preliminary Year End Information 2008

21 August 2008

AtCor Medical today released its 2008 Preliminary Year End Information.

Please click here to view the ASX/media release

AtCor Medical Announces FY2008 Record Sales

30 July 2008

AtCor Medical today announced record 2008 sales of $6.5m, an increase of 47% on a constant currency basis over the prior period, and in line with expectations. Second half sales soared 70% on a constant currency basis over pcp.

Please click here to view the ASX/media release

AtCor Medical Announces Fourth Quarter Report - Appendix 4C

30 July 2008

AtCor Medical today released its quarterly cash flow report for the period ending 30 June 2008.

Please click here to view the ASX/media release

US $1.6m New Pharmaceutical Trials Contracts

24 July 2008

AtCor Medical today announced that it has signed two new agreements to supply SphygmoCor® systems and clinical trial support services to a leading international pharmaceutical company. The minimum total value of these contracts is USD$1.6 million, the majority of which will be recognised in the current financial year. These new orders bring the minimum total value of pharmaceutical trial contracts secured by AtCor over the past 60 days to over US $2.8 million.

Please click here to view the ASX/media release

US $1.15m New Pharmaceutical Trials Contracts

4 June 2008

AtCor Medical today announced that it has signed agreements to supply SphygmoCor® systems and clinical trial support services for upcoming pharmaceutical clinical trials. The minimum total value of these contracts is USD$1.15 million, a significant portion of which will be recognised as revenue in the current financial year. Over 70 percent of these transactions are repeat business following successful use of SphygmoCor® in earlier trials by the same client company. The new trials will take place at sites in the US and Europe.

Please click here to view the ASX/media release

Study Findings: 70% with ‘High Normal’ Blood Pressure at Risk

20 May 2008

A new study of more than 10,000 patients has found more than 70 per cent of patients identified as having ‘high-normal’ blood pressure through traditional cuff blood pressure measurement may be at risk because they have elevated central blood pressure associated with increased incidence of heart attack, stroke and kidney disease.

Please click here to view the ASX/media release

AtCor Medical Receives Russian Marketing Approval

7 May 2008

AtCor Medical announced today that it has received formal certification from the Russian Ministry of Health, allowing AtCor to market its SphygmoCor® non-invasive central blood pressure systems throughout Russia - a Potential Market of 400 systems over the next 3 years.

Please click here to view the ASX/media release

New Study Shows Central Blood Pressure Is Superior

23 April 2008

A new study has found that elevated Central Blood Pressure is superior to arm blood pressure, high cholesterol, and smoking as a predictor of heart attacks and strokes.

Please click here to view the ASX/media release

AtCor Medical Announces Third Quarter Report - Appendix 4C

15 April 2008

AtCor Medical today released its quarterly cash flow report for the period ending 31 March 2008.

Please click here to view the ASX/media release

Investor Presentation

10 April 2008

AtCor Medical today released their Investor Presentation for 2008.

Please click here to view the ASX/media release

AtCor Medical Released Half Year Results

22 February 2008

AtCor Medical Holdings Limited today released its H1 FY2008 results showing record sales of $3.1 million for the period.

Please click here to view the ASX/media release

AtCor Medical announces Record Half Year Sales - On track for 50% sales growth in FY

24 January 2008

AtCor Medical Holdings Limited today announced unaudited H1 FY2008 sales of $3.1 million, a 27 per cent increase in constant currency over H1 FY2007 and a record for the company.

Please click here to view the ASX/media release

AtCor Medical announces second quarter report - Appendix 4C

24 January 2008

AtCor Medical today released its quarterly cash flow report for the period ending 31 December 2007. The company has $4,571,000 in cash and equivalents.

Please click here to view the ASX/media release